

AVACEN MEDICAL ANNOUNCES NEW ALLOWANCE OF PATENT CLAIMS

*EVALUATING BLOOD CIRCULATION AND
EARLY DETECTION OF CARDIOVASCULAR
ISSUES*

CARLSBAD, CALIFORNIA, UNITED
STATES, February 14, 2023

/EINPresswire.com/ -- [AVACEN Medical](#),
a leading manufacturer of noninvasive,
drug-free, FDA-Cleared, Class II,
thermotherapy devices, announced
today the U.S. Patent and Trademark
Office issuance of a notice of allowance
of claims associated with AVACEN
application US15/887,951 covering
Systems and Methods for Evaluating
Blood Circulation and Early Detection of Cardiovascular Issues.



"AVACEN Medical is pleased to add a 19th patent to our intellectual property portfolio," said Anthony Shimkin, President & CEO of AVACEN Medical.

“

Integrating a
robust/economical system
into our current and
planned product line to
monitor blood circulation
and detect at-risk patients
experiencing early signs of
potential cardiovascular
issues.”

Thomas G. Muehlbauer

“Our products continue to fill a valuable market need in helping users manage pain and wellness issues noninvasively. With over 8,000 devices field tested and over 20 million treatments without a reportable event to date, customer support for our award-winning products continues to grow. It is very rewarding to have the opportunity to dramatically improve our users’ quality of life.”

Thomas Muehlbauer, inventor and Chairman of AVACEN Medical stated, "These new patent claims address integrating a robust and economical system into our

current and planned product line to monitor blood circulation and detect at-risk patients experiencing early signs of potential cardiovascular issues. We will also be able to identify healthy patients in order to sidestep costly evaluations and risky treatments until potential

cardiovascular issues can be firmly diagnosed."

AVACEN's newest third generation devices include the HOME XL™ for users in a home-based environment, as well as the PRO+™ for professional users, including a commercial license to charge for treatments. The Company also recently launched its first cardiac diagnostic device, the CSS™ or Cardiac Stress & Screening. The device provides a 1, 3, and 5-minute test to examine arterial health and heart rate variability.

About AVACEN Medical: AVACEN Medical, a rapidly rising INC. 5000 company for the last three years, is dedicated to the innovation and design of safe, easy-to-use, drug-free alternatives for the noninvasive management of pain and wellness associated with numerous chronic and acute conditions including the temporary relief of minor muscle and joint pain and stiffness associated with [arthritis](#) and potentially other conditions that can cause joint pain, such as CRPS, Raynaud's, and Lyme disease. Founded in 2009, AVACEN Medical is headquartered in Carlsbad, CA. Contact: Danielle Forsgren, CMO at (888) 428-2236 x702 or djforsgren@avacen.com.

Thomas Muehlbauer

AVACEN Medical

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[Instagram](#)



AVACEN Home Device

This press release can be viewed online at: <https://www.einpresswire.com/article/617027052>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.